Logo

Chimerix's Tembexa (brincidofovir) Receives the US FDA's Approval for the Treatment of Smallpox

Share this

Chimerix's Tembexa (brincidofovir) Receives the US FDA's Approval for the Treatment of Smallpox

Shots:

  • The approval is based on efficacy data in two lethal orthopoxvirus animal models- i.e rabbitpox model & mousepox model evaluating Tembexa (100 mg- PO- tablets & 10 mg/mL oral suspension dosed- given once weekly for 2 wks.) vs PBO in adult & pediatric patients with Smallpox
  • The studies for each model showed that the therapy resulted in significant survival- following delayed treatment after animals were infected with a lethal viral dose.
  • Tembexa is the First smallpox antiviral approved for all age groups- including infants- and patients who have difficulty in swallowing. The therapy is being developed under an ongoing collaboration with BARDA

  Ref: Chimerix | Image: Chimerix

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions